Biological and predictive role of ERCC1 polymorphisms in cancer

被引：16

作者：

Formica, V. ^{[1
]}

Doldo, E. ^{[2
]}

Antonetti, F. R. ^{[1
]}

Nardecchia, A. ^{[1
]}

Ferroni, P. ^{[3
]}

Riondino, S. ^{[1
,3
]}

Morelli, C. ^{[1
]}

Arkenau, H. T. ^{[4
]}

Guadagni, F. ^{[3
]}

Orlandi, A. ^{[2
]}

Roselli, M. ^{[1
]}

机构：

[1] Tor Vergata Clin Ctr Univ Hosp, Dept Syst Med, Med Oncol Unit, Viale Oxford 81, I-00133 Rome, Italy

[2] Tor Vergata Univ Hosp, Inst Pathol Anat, Dept Biomed & Prevent, Rome, Italy

[3] San Raffaele Roma Open Univ, Dept Human Sci & Qual Life Promot, Rome, Italy

[4] Sarah Cannon Res Inst, Drug Dev Unit, London, England

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2017年 / 111卷

关键词：

ERCC1; Oxaliplatin; Single nucleotide polymorphisms; Colorectal cancer; NUCLEOTIDE EXCISION-REPAIR; ADVANCED COLORECTAL-CANCER; RELATIVE DOSE INTENSITY; MESSENGER-RNA LEVELS; GENE-SPECIFIC REPAIR; DNA-REPAIR; ADJUVANT CHEMOTHERAPY; XERODERMA-PIGMENTOSUM; OXALIPLATIN; CISPLATIN;

D O I：

10.1016/j.critrevonc.2017.01.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Excision repair cross-complementation group 1 (ERCCI) is a key component in DNA repair mechanisms and may influence the tumor DNA-targeting effect of the chemotherapeutic agent oxaliplatin. Germline ERCCI polymorphisms may alter the protein expression and published data on their predictive and prognostic value have so far been contradictory. In the present article we review available evidence on the clinical role and utility of ERCC1 polymorphisms and, in the absence of a 'perfect' trial, what we call the 'sliding doors' trial, we present the data of ERCC1 genotyping in our local patient population. We found a useful predictive value for oxaliplatin-induced risk of anemia. (C) 2017 Elsevier B.V. All rights reserved.

引用

页码：133 / 143

页数：11

共 54 条

[1] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[2] Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans [J].

Aspinall, Sherrie L. ;

Good, Chester B. ;

Zhao, Xinhua ;

Cunningham, Francesca E. ;

Heron, Bernadette B. ;

Geraci, Mark ;

Passero, Vida ;

Stone, Roslyn A. ;

Smith, Kenneth J. ;

Rogers, Renee ;

Shields, Jenna ;

Sartore, Megan ;

Boyle, D. Patrick ;

Giberti, Sherry ;

Szymanski, John ;

Smith, Doug ;

Ha, Allen ;

Sessions, Jolynn ;

Depcinski, Shawn ;

Fishco, Shane ;

Molina, Irvin ;

Lepir, Tanja ;

Jean, Carmela ;

Cruz-Diaz, Lymaris ;

Motta, Jessica ;

Calderon-Vargas, Rebeca ;

Maland, Janelle ;

Keefe, Sean ;

Tague, Marshall ;

Leone, Alice ;

Glovack, Brian ;

Kaplan, Blair ;

Cosgriff, Sean ;

Kaster, Lindsay ;

Tonnu-Mihara, Ivy ;

Nguyen, Kimmai ;

Carmichael, Jenna ;

Clifford, Linda ;

Lu, Kan ;

Chatta, Gurkamal .

BMC CANCER, 2015, 15

[3] Immunodetection of DNA Repair Endonuclease ERCC1-XPF in Human Tissue [J].

Bhagwat, Nikhil R. ;

Roginskaya, Vera Y. ;

Acquafondata, Marie B. ;

Dhir, Rajiv ;

Wood, Richard D. ;

Niedernhofer, Laura J. .

CANCER RESEARCH, 2009, 69 (17) :6831-6838

[4] Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05 [J].

Boige, Valerie ;

Mendiboure, Jean ;

Pignon, Jean-Pierre ;

Loriot, Marie-Anne ;

Castaing, Marine ;

Barrois, Michel ;

Malka, David ;

Tregouet, David-Alexandre ;

Bouche, Olivier ;

Le Corre, Delphine ;

Miran, Isabelle ;

Mulot, Claire ;

Ducreux, Michel ;

Beaune, Philippe ;

Laurent-Puig, Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) :2556-2564

[5] Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy? [J].

Bowden, Nikola A. .

CANCER LETTERS, 2014, 346 (02) :163-171

[6]

BRAMSON J, 1993, CANCER RES, V53, P3237

[7] Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial [J].

Braun, Michael S. ;

Richman, Susan D. ;

Quirke, Philip ;

Daly, Catherine ;

Adlard, Julian W. ;

Elliott, Faye ;

Barrett, Jennifer H. ;

Selby, Peter ;

Meade, Angela M. ;

Stephens, Richard J. ;

Parmar, Mahesh K. B. ;

Seymour, Matthew T. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) :2690-2698

[8] Colorectal cancer [J].

Brenner, Hermann ;

Kloor, Matthias ;

Pox, Christian Peter .

LANCET, 2014, 383 (9927) :1490-1502

[9] Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial [J].

Butler, L ;

Bacon, M ;

Carey, M ;

Zee, B ;

Tu, DS ;

Bezjak, A .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2461-2468

[10] ERCC1 AND ERCC2 EXPRESSION IN MALIGNANT-TISSUES FROM OVARIAN-CANCER PATIENTS [J].

DABHOLKAR, M ;

BOSTICKBRUTON, F ;

WEBER, C ;

BOHR, VA ;

EGWUAGU, C ;

REED, E .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (19) :1512-1517

← 1 2 3 4 5 6 →